DaVita (NYSE:DVA) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of DaVita (NYSE:DVA) from a hold rating to a buy rating in a research note released on Saturday morning.

Several other brokerages also recently issued reports on DVA. Barclays boosted their price objective on DaVita from $143.00 to $158.00 and gave the stock an “equal weight” rating in a research report on Tuesday, February 3rd. TD Cowen reiterated a “hold” rating on shares of DaVita in a research report on Tuesday, February 3rd. Zacks Research raised DaVita from a “hold” rating to a “strong-buy” rating in a report on Wednesday, February 4th. Weiss Ratings restated a “hold (c)” rating on shares of DaVita in a research note on Monday, December 29th. Finally, Truist Financial set a $158.00 target price on shares of DaVita in a research note on Thursday, February 5th. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $155.80.

DaVita Price Performance

Shares of DVA opened at $151.16 on Friday. DaVita has a 12 month low of $101.00 and a 12 month high of $157.12. The stock has a fifty day moving average price of $121.34 and a 200 day moving average price of $125.32. The company has a market cap of $10.10 billion, a P/E ratio of 15.25, a PEG ratio of 0.53 and a beta of 0.99.

DaVita (NYSE:DVA) last announced its quarterly earnings results on Monday, February 2nd. The company reported $3.40 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.24 by $0.16. The company had revenue of $3.62 billion during the quarter, compared to the consensus estimate of $3.51 billion. DaVita had a net margin of 5.47% and a negative return on equity of 413.18%. The company’s revenue for the quarter was up 9.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.24 earnings per share. DaVita has set its FY 2026 guidance at 13.600-15.00 EPS. As a group, research analysts anticipate that DaVita will post 10.76 earnings per share for the current year.

Institutional Trading of DaVita

A number of hedge funds and other institutional investors have recently made changes to their positions in DVA. NewEdge Advisors LLC lifted its stake in DaVita by 20.8% during the first quarter. NewEdge Advisors LLC now owns 511 shares of the company’s stock valued at $78,000 after buying an additional 88 shares in the last quarter. Goldman Sachs Group Inc. raised its holdings in shares of DaVita by 19.1% during the first quarter. Goldman Sachs Group Inc. now owns 179,140 shares of the company’s stock valued at $27,403,000 after acquiring an additional 28,739 shares during the period. DekaBank Deutsche Girozentrale lifted its position in shares of DaVita by 8.4% in the 2nd quarter. DekaBank Deutsche Girozentrale now owns 14,013 shares of the company’s stock valued at $1,991,000 after acquiring an additional 1,084 shares in the last quarter. Ethic Inc. boosted its stake in DaVita by 36.9% in the 2nd quarter. Ethic Inc. now owns 3,091 shares of the company’s stock worth $438,000 after purchasing an additional 833 shares during the period. Finally, Sumitomo Mitsui Trust Group Inc. grew its position in DaVita by 4.0% during the 2nd quarter. Sumitomo Mitsui Trust Group Inc. now owns 113,503 shares of the company’s stock worth $16,169,000 after purchasing an additional 4,404 shares in the last quarter. 90.12% of the stock is currently owned by institutional investors.

DaVita Company Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.